


National Resilience and Taiwan Bio-Manufacturing Corporation partners in Biomanufacturing Innovation

05 February 2024 | News

This joint venture to develop modern technology-enabled manufacturing solutions tailored for advanced the rapeutic modalities including biologics, vaccines, nucleic acids, cell the rapy, and gene the rapy



National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, and Taiwan Bio-Manufacturing Corporation (TBMC), has entered a groundbreaking joint venture to transform the biomanufacturing industry. The collaboration addresses the growing need for technology-enabled, end-to-end solutions for complex medicines.

In recent years, the biomedical industry has made incredible strides in developing increasingly complex medicines. However, large-scale biomanufacturing processes have struggled to keep pace with the ability to produce these new, complex therapies. Recognizing this gap, Resilience and TBMC will join forces to provide an effective path forward for the efficient production of next-generation treatments.

TBMC aims to transform biomanufacturing by combining the technological capabilities of Resilience with Taiwan's renowned expertise in automation, excellence in digital manufacturing and highly skilled life sciences workforce. This joint venture focuses on developing modern technology-enabled manufacturing solutions tailored for advanced therapeutic modalities including biologics, vaccines, nucleic acids, cell therapy, and gene therapy.

As part of the collaboration, Resilience will license certain manufacturing technology platforms in all five of its therapeutic modalities to TBMC and will provide invaluable support in designing and constructing cGMP (current Good Manufacturing Practices) facilities and process development laboratories for the joint venture. In return, Resilience becomes an equity shareholder of TBMC, fostering a close partnership to develop advanced manufacturing technologies for complex modalities and drive innovation in the industry.

The partnership between Resilience and TBMC represents a significant milestone in the Contract Development and Manufacturing Organization (CDMO) industry underscoring the commitment of both organizations to drive innovation in biomanufacturing, meet the growing demand for complex medicines and deliver life-changing therapies to patients worldwide.